<DOC>
	<DOC>NCT02285361</DOC>
	<brief_summary>To monitor the safety profile and efficacy of GIOTRIF®(afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)</brief_summary>
	<brief_title>GIOTRIF rPMS in Korean Patients With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criteria: 1. Patients who have been started on GIOTRIF® in accordance with the approved label in Korea 2. Age = 19 years at enrolment 3. Patients who have signed on the data release consent form Exclusion criteria: 1. Known hypersensitivity to afatinib or any of its excipients 2. Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption 3. Patients for whom GIOTRIF® is contraindicated according to the local label</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>